ALEC Stock Overview
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.17|
|52 Week High||US$43.32|
|52 Week Low||US$15.04|
|1 Month Change||-30.72%|
|3 Month Change||-31.86%|
|1 Year Change||-7.28%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-10.17%|
Recent News & Updates
Alector: The GSK Deal Is A Major Value Add
Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK. Early stage positive data makes it very attractive.
|ALEC||US Biotechs||US Market|
Return vs Industry: ALEC exceeded the US Biotechs industry which returned -18.4% over the past year.
Return vs Market: ALEC underperformed the US Market which returned 10.2% over the past year.
|ALEC Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||10.1%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ALEC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ALEC's weekly volatility (9%) has been stable over the past year.
About the Company
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer’s disease.
Alector Fundamentals Summary
|ALEC fundamental statistics|
Is ALEC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALEC income statement (TTM)|
|Cost of Revenue||US$181.00m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-16.62%|
How did ALEC perform over the long term?See historical performance and comparison
Is Alector undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALEC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALEC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALEC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALEC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALEC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALEC is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (2.1x).
How is Alector forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALEC's earnings are forecast to decline over the next 3 years (-52.6% per year).
Earnings vs Market: ALEC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALEC's is expected to become profitable in the next 3 years.
Revenue vs Market: ALEC's revenue is expected to decline over the next 3 years (-8.6% per year).
High Growth Revenue: ALEC's revenue is forecast to decline over the next 3 years (-8.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALEC is forecast to be unprofitable in 3 years.
How has Alector performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALEC is currently unprofitable.
Growing Profit Margin: ALEC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALEC is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare ALEC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALEC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ALEC has a negative Return on Equity (-9.79%), as it is currently unprofitable.
How is Alector's financial position?
Financial Position Analysis
Short Term Liabilities: ALEC's short term assets ($788.0M) exceed its short term liabilities ($132.8M).
Long Term Liabilities: ALEC's short term assets ($788.0M) exceed its long term liabilities ($385.5M).
Debt to Equity History and Analysis
Debt Level: ALEC is debt free.
Reducing Debt: ALEC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALEC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALEC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 29.6% per year.
What is Alector current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALEC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALEC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALEC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALEC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALEC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Arnon Rosenthal (65 yo)
Dr. Arnon Rosenthal, Ph D., Co-Founded of in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Alector,...
CEO Compensation Analysis
Compensation vs Market: Arnon's total compensation ($USD3.66M) is about average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Arnon's compensation has been consistent with company performance over the past year.
Experienced Management: ALEC's management team is considered experienced (3 years average tenure).
Experienced Board: ALEC's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ALEC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.
Alector, Inc.'s employee growth, exchange listings and data sources
- Name: Alector, Inc.
- Ticker: ALEC
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.314b
- Shares outstanding: 81.28m
- Website: https://www.alector.com
Number of Employees
- Alector, Inc.
- 131 Oyster Point Boulevard
- Suite 600
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 23:49|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.